Market Closed -
Warsaw S.E.
16:55:55 07/05/2024 BST
|
5-day change
|
1st Jan Change
|
42.6
PLN
|
-0.12%
|
|
+0.24%
|
+2.65%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
114.4
|
105.4
|
4,469
|
1,033
|
525.4
|
441.9
|
Enterprise Value (EV)
1 |
249.4
|
238.8
|
3,926
|
502.3
|
107
|
120.4
|
P/E ratio
|
15.3
x
|
-45.2
x
|
4.78
x
|
2.2
x
|
-2.54
x
|
-17.4
x
|
Yield
|
-
|
5.03%
|
-
|
-
|
5.07%
|
-
|
Capitalization / Revenue
|
0.27
x
|
0.19
x
|
2.43
x
|
0.6
x
|
0.97
x
|
0.86
x
|
EV / Revenue
|
0.59
x
|
0.44
x
|
2.14
x
|
0.29
x
|
0.2
x
|
0.23
x
|
EV / EBITDA
|
8.96
x
|
10.2
x
|
3.69
x
|
1.04
x
|
-2.11
x
|
-1.85
x
|
EV / FCF
|
-4.26
x
|
24.9
x
|
9.37
x
|
2.57
x
|
-1.06
x
|
-3.32
x
|
FCF Yield
|
-23.5%
|
4.02%
|
10.7%
|
38.9%
|
-93.9%
|
-30.1%
|
Price to Book
|
0.86
x
|
0.79
x
|
4.22
x
|
0.9
x
|
0.52
x
|
0.21
x
|
Nbr of stocks (in thousands)
|
10,589
|
10,589
|
10,589
|
10,647
|
10,647
|
10,647
|
Reference price
2 |
10.80
|
9.950
|
422.0
|
97.00
|
49.35
|
41.50
|
Announcement Date
|
25/03/19
|
30/03/20
|
17/03/21
|
14/04/22
|
02/05/23
|
29/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
420.4
|
540.3
|
1,835
|
1,729
|
542.8
|
514.7
|
EBITDA
1 |
27.84
|
23.35
|
1,065
|
481.3
|
-50.74
|
-65
|
EBIT
1 |
14.19
|
6.982
|
1,047
|
463
|
-74.75
|
-87.12
|
Operating Margin
|
3.38%
|
1.29%
|
57.05%
|
26.77%
|
-13.77%
|
-16.93%
|
Earnings before Tax (EBT)
1 |
8.131
|
2.069
|
1,041
|
477.2
|
-186.2
|
-3.792
|
Net income
1 |
7.468
|
-2.328
|
930.2
|
446.9
|
-189.6
|
-19.68
|
Net margin
|
1.78%
|
-0.43%
|
50.68%
|
25.84%
|
-34.94%
|
-3.82%
|
EPS
2 |
0.7053
|
-0.2200
|
88.33
|
44.15
|
-19.41
|
-2.380
|
Free Cash Flow
1 |
-58.55
|
9.599
|
418.7
|
195.4
|
-100.5
|
-36.26
|
FCF margin
|
-13.93%
|
1.78%
|
22.82%
|
11.3%
|
-18.52%
|
-7.04%
|
FCF Conversion (EBITDA)
|
-
|
41.11%
|
39.32%
|
40.6%
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
45.02%
|
43.73%
|
-
|
-
|
Dividend per Share
|
-
|
0.5000
|
-
|
-
|
2.500
|
-
|
Announcement Date
|
25/03/19
|
30/03/20
|
17/03/21
|
14/04/22
|
02/05/23
|
29/04/24
|
Fiscal Period: December |
2022 Q2
|
2022 Q3
|
---|
Net sales
1 |
-
|
168.5
|
EBITDA
1 |
-
|
8.012
|
EBIT
1 |
-
|
1.165
|
Operating Margin
|
-
|
0.69%
|
Earnings before Tax (EBT)
|
-
|
-
|
Net income
|
-11.12
|
-
|
Net margin
|
-
|
-
|
EPS
|
-1.140
|
-
|
Dividend per Share
|
-
|
-
|
Announcement Date
|
30/09/22
|
29/11/22
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
135
|
133
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
543
|
530
|
418
|
321
|
Leverage (Debt/EBITDA)
|
4.851
x
|
5.717
x
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-58.6
|
9.6
|
419
|
195
|
-101
|
-36.3
|
ROE (net income / shareholders' equity)
|
5.57%
|
-1.55%
|
159%
|
40.7%
|
-17.7%
|
-2.44%
|
ROA (Net income/ Total Assets)
|
2.64%
|
1.14%
|
78.1%
|
22.4%
|
-3.94%
|
-5.32%
|
Assets
1 |
282.6
|
-203.5
|
1,191
|
1,991
|
4,813
|
370.1
|
Book Value Per Share
2 |
12.50
|
12.60
|
99.90
|
107.0
|
94.70
|
202.0
|
Cash Flow per Share
2 |
1.530
|
1.400
|
38.40
|
31.90
|
21.00
|
51.00
|
Capex
1 |
43.1
|
15.6
|
15.5
|
177
|
110
|
39.1
|
Capex / Sales
|
10.24%
|
2.88%
|
0.84%
|
10.22%
|
20.2%
|
7.59%
|
Announcement Date
|
25/03/19
|
30/03/20
|
17/03/21
|
14/04/22
|
02/05/23
|
29/04/24
|
|
1st Jan change
|
Capi.
|
---|
| +2.65% | 104M | | -29.70% | 3.15B | | -15.57% | 2.57B | | +21.75% | 2.55B | | +7.04% | 2.09B | | -1.13% | 2.04B | | -0.56% | 1.53B | | +0.80% | 1.33B | | +23.78% | 1.23B | | +4.72% | 1.16B |
Medical Supplies
|